

Table SI. Baseline and patient characteristics of the patients who could have reached week 16

Baseline characteristics	Total cohort	Dup-naïve/R	Dup-NR	Upa-naïve/R	Upa-NR
N	78	41	37	57	21
Age years, mean (SD)	36.9 (14.2)	35.6 (11.8)	38.3 (16.5)	37.3 (14.9)	35.8 (12.4)
Sex, n (%)					
Male	50 (64.1)	27 (65.9)	23 (62.2)	36 (63.2)	14 (66.7)
Female	28 (35.9)	14 (34.1)	14 (37.8)	21 (36.8)	7 (33.3)
Atopic comorbidities, n (%)					
Allergic asthma	49 (62.8)	26 (63.4)	23 (62.2)	34 (59.6)	15 (71.4)
Allergic rhinitis	52 (66.7)	26 (63.4)	26 (70.3)	36 (63.2)	16 (76.2)
Allergic conjunctivitis	44 (56.4)	25 (61.0)	19 (51.4)	28 (49.1)	16 (76.2)
Food allergy	33 (42.3)	17 (41.5)	16 (43.2)	20 (35.1)	13 (61.9)
≥2 atopic comorbidities	52 (66.7)	29 (70.7)	23 (62.2)	34 (59.6)	18 (85.7)
AD age of onset, n (%)					
Childhood (≤ 12 years)	67 (85.9)	33 (80.5)	34 (91.9)	48 (84.2)	19 (90.5)
Adolescence (13 to <18 years)	5 (6.4)	4 (9.8)	1 (2.7)	4 (7.0)	1 (4.8)
Adult (≥18 years)	6 (7.7)	4 (9.8)	2 (5.4)	5 (8.8)	1 (4.8)
Previous use of conventional immunosuppressive drugs, n (%)					
Azathioprine	6 (7.7)	2 (4.9)	4 (10.8)	5 (8.8)	1 (4.8)
Cyclosporine A	73 (93.6)	38 (92.7)	35 (94.6)	53 (93.0)	20 (95.2)
Methotrexate	34 (43.6)	19 (46.3)	15 (40.5)	23 (40.4)	11 (52.4)
Mycophenolate mofetil	7 (6.8)	1 (2.4)	6 (16.2)	5 (8.8)	2 (9.5)
Tacrolimus (oral)	1 (1.3)	0 (0.0)	1 (2.7)	0 (0.0)	1 (4.8)
History of ≥ 2 immunosuppressives	36 (46.2)	18 (43.9)	18 (48.6)	24 (42.1)	12 (57.1)
In wash-out of immunosuppressive therapy at baseline, n (%)	40 (51.3)	21 (51.2)	19 (51.4)	27 (47.4)	13 (61.9)

Baricitinib	3 (3.8)	2 (4.9)	1 (2.7)	3 (5.3)	0 (0.0)
Cyclosporin A	2 (2.6)	0 (0.0)	2 (5.4)	2 (3.5)	0 (0.0)
Dupilumab	14 (17.9)	5 (12.2)	9 (24.3)	13 (22.8)	1 (4.8)
Hydrocortisone	1 (1.3)	1 (2.4)	0 (0.0)	0 (0.0)	1 (4.8)
Methotrexate	4 (5.1)	3 (7.3)	1 (2.7)	4 (7.0)	0 (0.0)
Prednisolone	3 (3.8)	1 (2.4)	2 (5.4)	2 (3.5)	1 (4.8)
Tralokinumab	2 (2.6)	2 (4.9)	0 (0.0)	1 (1.8)	1 (4.8)
Upadacitinib	12 (15.4)	8 (19.5)	4 (10.8)	2 (3.5)	10 (47.6)
EASI score, mean (SD)	17.6 (12.2)	17.8 (13.2)	17.4 (11.2)	17.5 (12.8)	17.9 (10.6)
IGA score, n (%)					
Almost clear	1 (1.3)	1 (2.4)	0 (0.0)	1 (1.8)	0 (0.0)
Mild	11 (14.1)	7 (17.1)	4 (10.8)	10 (17.9)	1 (4.8)
Moderate	31 (39.7)	15 (36.6)	16 (43.2)	23 (41.1)	8 (38.1)
Severe	22 (28.2)	11 (26.8)	11 (29.7)	13 (23.2)	9 (42.9)
Very severe	10 (12.8)	6 (14.6)	4 (10.8)	8 (14.3)	2 (9.5)
NRS-pruritus, mean (SD)	7.0 (2.2)	7.4 (2.2)	6.5 (2.0)	6.8 (2.3)	7.5 (1.8)
NRS-pain, mean (SD)	4.5 (3.3)	4.7 (3.2)	4.2 (3.5)	4.4 (3.3)	4.8 (3.4)
DLQI score, mean (SD)	13.2 (7.9)	14.4 (7.5)	11.9 (8.2)	11.7 (7.8)	17.4 (6.5)
POEM score, mean (SD)	18.5 (7.0)	19.0 (6.9)	17.9 (7.2)	17.5 (7.3)	21.2 (5.4)
ADCT score, mean (SD)	12.7 (6.6)	14.0 (6.8)	10.9 (6.1)	11.5 (6.6)	16.8 (5.1)
PGAD score, n (%)					
Poor	9 (11.5)	7 (17.1)	2 (5.4)	4 (7.0)	5 (23.8)
Fair	25 (32.1)	14 (34.1)	11 (29.7)	18 (31.6)	7 (33.3)
Good	16 (20.5)	6 (14.6)	10 (27.0)	16 (28.1)	0 (0.0)
Very good	1 (1.3)	0 (0.0)	1 (2.7)	1 (1.8)	0 (0.0)
Excellent	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Dup: dupilumab; upa: upadacitinib; NR: non-responders; naïve/R: naïve patients/responders; n: number; SD: standard deviation; AD: atopic dermatitis; EASI: Eczema Area and Severity Index; IGA: Investigator Global Assessment; NRS: Numeric Rating Scale; DLQI: Dermatology Life Quality Index; POEM: Patient-Oriented Eczema Measure; ADCT: Atopic Dermatitis Control Tool; PGAD: Patient Global Assessment of Disease